OCEANSIDE, CA--(Marketwired - Aug 31, 2015) - Therapeutics Solutions International (
OmniBiome was founded in 2013 by David Palella, Alan Lewis, and Thomas Ichim with the mission of being "the world's first biotech company focused on developing proprietary diagnostic, medical device and therapeutic approaches to either utilize -- or intervene with -- the systemic effects of the vaginal, lactal-duct and oral microbiomes for improving maternal and fetal healthcare."
"We are eager to continue the work of OmniBiome founder, the late David Palella, who assembled a multi-disciplinary team of experts to develop probiotic and microbiome technologies that address an underserved but significant area of health care: maternal-fetal medicine," said Tim Dixon, President and CEO of Therapeutic Solutions International. "The current acquisition fits in closely with our recently filed patent covering probiotic-based immune modulation for prevention of recurrent spontaneous abortions, and is complementary to the overall goal of the company, which is to provide natural-based immune modulators for treatment of unmet medical needs in niche markets."
Several studies have demonstrated that immune mediated inflammation is a major cause of preterm labor and pregnancy complications (1,2,3). Furthermore alterations in the microbiome have been shown to elicit profound changes on the immune system (4), which according to the intellectual property acquired, can be utilized therapeutically in the context of pregnancy complications and preterm labor.
About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
1 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249583/
2 http://www.ncbi.nlm.nih.gov/pubmed/25802092
3 http://www.ncbi.nlm.nih.gov/pubmed/24954221
4 http://www.ncbi.nlm.nih.gov/pubmed/24678760
Contact Information:
Therapeutic Solutions International, Inc.
ir@tsoimail.com